Dr Arjun Muralidharan

B.Pharm (Hons.), Ph.D. (Neuropharmacology)
Postdoctoral Research Associate
School of Life and Environmental Sciences

D17 - Charles Perkins Centre
The University of Sydney

Telephone +61 2 8627 7632

Website Neely Lab

Biographical details

Dr Muralidharan completed his PhD from the laboratory of Professor Maree T. Smith at The University of Queensland in 2013. Subsequently, he then undertook his first postdoctoral tenure at the Centre for Integrated Preclinical Drug Development (CIPDD; UQ) funded by a Large ARC Linkage Grant in collaboration with Boehringer Ingelheim GmbH. In 2015, he was awarded the Ronald Melzack Fellowship in Chronic Pain to pursue his second postdoctoral tenure in the Pain Genetics laboratory of Professor Jeffrey S. Mogil at McGill University (Canada). He is now a postdoctoral research fellow in Dr. John and Anne Chong Functional Genomics laboratory of Associate Professor Greg Neely at University of Sydney. Currently, his research work focuses on molecular dissection of the interplay between chronic pain and ageing.

Research interests

Chronic pain is the most prevalent human health problem by far, and dwarfs most other diseases in terms of morbidity and mortality. In fact, chronic pain exceeds heart disease, diabetes, and cancer combined in terms of prevalence and economic burden.However, available treatments for pain are often ineffective and associated with dose-limiting side-effects, and new pain treatments are sorely needed.

Dr Muralidharan’s research aims to understand the pathobiological mechanisms that underlie effective pain perception and to identify novel ‘pain targets’ to better treat this disease condition. To reach these goals, he combines a variety of experimental approaches including molecular and cellular biology, pharmacology, genetics and behaviour.

Associations

  • International Association for the Study on Pain (IASP)
  • Australian Pain Society

Awards and honours

  • 2019 – Rising Star Award: Australian Pain Society
  • 2017 – Best Poster Award: 21st Annual McGill Pain Day
  • 2015 – Ronald Melzack Fellowship in Chronic Pain
  • 2014 – IASP Travel Grant Award
  • 2012 – IASP Travel Grant Award
  • 2012 – Cancer Council Queensland Travel Grant Award
  • 2012 – ASCEPT Travel Grant Award
  • 2011 – Australian Pain Society: Travel Grant Award
  • 2011 – ASCEPT Travel Grant Award
  • 2011 – Best Research Higher Degree Publication of the Year Award
  • 2009 – International PhD research scholarship awards (UQIRTA and UQRS)

Themes

Genetics and genomics; Human health

Selected grants

2018

  • Sex-Dependent Role of Telomeres and Cellular Senescence in Pain in Mice and Humans; Mogil J, Muralidharan A; Canadian Institutes of Health Research (CIHR)/Catalyst Grant.

2015

  • Ronald Melzack Fellowship In Pain Research; Muralidharan A; Louis and Alan Edwards Foundation (Canada)/Ronald Melzack Fellowship in Pain Research.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Smith, M., Muralidharan, A. (2014). Pain pharmacology and the pharmacological management of pain. In Hubert van Griensven, Jenny Strong, Anita Unruh (Eds.), Pain: A textbook for health professionals (2nd ed.), (pp. 159-180). Edinburgh: Churchill Livingstone.
  • Smith, M., Muralidharan, A. (2013). Pharmacogenetics of Pain. In David N. Cooper (Eds.), eLS, (pp. 1-12). Chichester: John Wiley & Sons. [More Information]

Journals

  • Khan, N., Muralidharan, A., Smith, M. (2017). Attenuation of the infiltration of angiotensin II expressing CD3+ T-cells and the modulation of nerve growth factor in lumbar dorsal root ganglia - a possible mechanism underpinning analgesia produced by EMA300, an angiotensin II Type 2 (AT2) receptor antagonist. Frontiers in Molecular Neuroscience, 10, 1-16. [More Information]
  • Muralidharan, A., Park, T., Mackie, J., Gimenez, L., Kuo, A., Nicholson, J., Corradini, L., Smith, M. (2017). Establishment and characterization of a novel rat model of mechanical low back pain using behavioral, pharmacologic and histologic methods. Frontiers in Pharmacology, 8, 1-12. [More Information]
  • Muralidharan, A., Kuo, A., Jacob, M., Lourdesamy, J., Pinho de Carvalho, L., Nicholson, J., Corradini, L., Smith, M. (2016). Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience, 10, 1-9. [More Information]
  • Smith, M., Muralidharan, A. (2015). Targeting angiotensin II Type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion on Therapeutic Targets, 19(1), 25-35. [More Information]
  • Muralidharan, A., Wyse, B., Smith, M. (2014). Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist, in a rat model of prostate cancer-induced bone pain. Pain Medicine, 15(1), 93-110. [More Information]
  • Smith, M., Woodruff, T., Wyse, B., Muralidharan, A., Walther, T. (2013). A small molecule angiotensin II Type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen activated protein kinase (MAPK) and p42/p44 MAPK activation in the dorsal root ganglia. Pain Medicine, 14(10), 1557-1568. [More Information]
  • Smith, M., Muralidharan, A. (2013). Comment on "protective arms of the renin-angiotensin system in neurological disease". Clinical and Experimental Pharmacology and Physiology, 40(11), 838-838. [More Information]
  • Muralidharan, A., Wyse, B., Smith, M. (2013). Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioural, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology, Biochemistry and Behavior, 106, 33-46. [More Information]
  • Muralidharan, A., Smith, M. (2013). Pathobiology and Pharmacological Management of Prostate Cancer-Induced Bone Pain: Recent Insights and Future Treatments. Inflammopharmacology, 21(5), 339-363. [More Information]
  • Smith, M., Muralidharan, A. (2012). Pharmacogenetics of Pain and Analgesia. Clinical Genetics, 82(4), 321-330. [More Information]
  • Yogeeswari, P., Menon, N., Semwal, A., Muralidharan, A., Dharmarajan, S. (2011). Discovery of molecules for the treatment of neuropathic pain: Synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones. European Journal of Medicinal Chemistry, 46(7), 2964-2970. [More Information]
  • Muralidharan, A., Smith, M. (2011). Pain, Analgesia and Genetics. Journal of Pharmacy and Pharmacology, 63(11), 1387-1400. [More Information]
  • Pandey, D., Radhakrishnan, M., Akutota Ashok, K., Rao, V., Muralidharan, A., Ramamoorthy, R. (2010). A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacology, Biochemistry and Behavior, 94(3), 363-373. [More Information]
  • Smith, M., Muralidharan, A. (2010). Pharmacogenetics. Pain: Clinical Updates, XVII (8), 1-8.

2017

  • Khan, N., Muralidharan, A., Smith, M. (2017). Attenuation of the infiltration of angiotensin II expressing CD3+ T-cells and the modulation of nerve growth factor in lumbar dorsal root ganglia - a possible mechanism underpinning analgesia produced by EMA300, an angiotensin II Type 2 (AT2) receptor antagonist. Frontiers in Molecular Neuroscience, 10, 1-16. [More Information]
  • Muralidharan, A., Park, T., Mackie, J., Gimenez, L., Kuo, A., Nicholson, J., Corradini, L., Smith, M. (2017). Establishment and characterization of a novel rat model of mechanical low back pain using behavioral, pharmacologic and histologic methods. Frontiers in Pharmacology, 8, 1-12. [More Information]

2016

  • Muralidharan, A., Kuo, A., Jacob, M., Lourdesamy, J., Pinho de Carvalho, L., Nicholson, J., Corradini, L., Smith, M. (2016). Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience, 10, 1-9. [More Information]

2015

  • Smith, M., Muralidharan, A. (2015). Targeting angiotensin II Type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion on Therapeutic Targets, 19(1), 25-35. [More Information]

2014

  • Muralidharan, A., Wyse, B., Smith, M. (2014). Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist, in a rat model of prostate cancer-induced bone pain. Pain Medicine, 15(1), 93-110. [More Information]
  • Smith, M., Muralidharan, A. (2014). Pain pharmacology and the pharmacological management of pain. In Hubert van Griensven, Jenny Strong, Anita Unruh (Eds.), Pain: A textbook for health professionals (2nd ed.), (pp. 159-180). Edinburgh: Churchill Livingstone.

2013

  • Smith, M., Woodruff, T., Wyse, B., Muralidharan, A., Walther, T. (2013). A small molecule angiotensin II Type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen activated protein kinase (MAPK) and p42/p44 MAPK activation in the dorsal root ganglia. Pain Medicine, 14(10), 1557-1568. [More Information]
  • Smith, M., Muralidharan, A. (2013). Comment on "protective arms of the renin-angiotensin system in neurological disease". Clinical and Experimental Pharmacology and Physiology, 40(11), 838-838. [More Information]
  • Muralidharan, A., Wyse, B., Smith, M. (2013). Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioural, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology, Biochemistry and Behavior, 106, 33-46. [More Information]
  • Muralidharan, A., Smith, M. (2013). Pathobiology and Pharmacological Management of Prostate Cancer-Induced Bone Pain: Recent Insights and Future Treatments. Inflammopharmacology, 21(5), 339-363. [More Information]
  • Smith, M., Muralidharan, A. (2013). Pharmacogenetics of Pain. In David N. Cooper (Eds.), eLS, (pp. 1-12). Chichester: John Wiley & Sons. [More Information]

2012

  • Smith, M., Muralidharan, A. (2012). Pharmacogenetics of Pain and Analgesia. Clinical Genetics, 82(4), 321-330. [More Information]

2011

  • Yogeeswari, P., Menon, N., Semwal, A., Muralidharan, A., Dharmarajan, S. (2011). Discovery of molecules for the treatment of neuropathic pain: Synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones. European Journal of Medicinal Chemistry, 46(7), 2964-2970. [More Information]
  • Muralidharan, A., Smith, M. (2011). Pain, Analgesia and Genetics. Journal of Pharmacy and Pharmacology, 63(11), 1387-1400. [More Information]

2010

  • Pandey, D., Radhakrishnan, M., Akutota Ashok, K., Rao, V., Muralidharan, A., Ramamoorthy, R. (2010). A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacology, Biochemistry and Behavior, 94(3), 363-373. [More Information]
  • Smith, M., Muralidharan, A. (2010). Pharmacogenetics. Pain: Clinical Updates, XVII (8), 1-8.

To update your profile click here. For support on your academic profile contact .